Terms: = Lung cancer AND PSA
516 results:
1. The cost-effectiveness of iruplinalkib versus alectinib in anaplastic lymphoma kinase-positive crizotinib-resistant advanced non-small-cell lung cancer patients in China.
Dai Z; Xu J; Chang F; Zhou W; Ren T; Qiu J; Lu Y; Lu Y
Front Public Health; 2024; 12():1333487. PubMed ID: 38699428
[TBL] [Abstract] [Full Text] [Related]
2. [Exploration and validation of optimal cut-off values for tpsa and fpsa/tpsa screening of prostate cancer at different ages].
Liu XM; Duan HY; Zhang DQ; Chen C; Ji YT; Zhang YM; Feng ZW; Liu Y; Li JJ; Zhang Y; Li CY; Zhang YC; Yang L; Lyu ZY; Song FF; Song FJ; Huang YB
Zhonghua Zhong Liu Za Zhi; 2024 Apr; 46(4):354-364. PubMed ID: 38644271
[No Abstract] [Full Text] [Related]
3. Tumor promoting effect of spheroids in an orthotopic prostate cancer mouse model.
Bastian JLD; Zeuschner P; Stöckle M; Junker K; Linxweiler J
Sci Rep; 2024 Apr; 14(1):8835. PubMed ID: 38632341
[TBL] [Abstract] [Full Text] [Related]
4. Factors influencing blood tumor marker concentrations in the absence of neoplasia.
Trapé J; Fernández-Galán E; Auge JM; Carbonell-Prat M; Filella X; Miró-Cañís S; González-Fernández C;
Tumour Biol; 2024; 46(s1):S35-S63. PubMed ID: 38517826
[TBL] [Abstract] [Full Text] [Related]
5. Economic evaluation of cemiplimab plus chemotherapy regimen for advanced non-small-cell lung cancer.
Lang Y; Lin Y; Deng M; Liu X
BMC Cancer; 2024 Feb; 24(1):236. PubMed ID: 38383374
[TBL] [Abstract] [Full Text] [Related]
6. Ductal prostate cancer staging: Role of PSMA PET/CT.
Pepe P; Pepe L; Curduman M; Pennisi M; Fraggetta F
Arch Ital Urol Androl; 2024 Feb; 96(1):12132. PubMed ID: 38363231
[TBL] [Abstract] [Full Text] [Related]
7. Copy Number Gain in Androgen Receptors Predicts the Poor Prognosis in Japanese Castration-resistant Prostate cancer.
Sakamoto S; Ando K; Pae S; Zhao X; Sakai K; Sato K; Saito S; Yamada Y; Rii J; Goto Y; Sazuka T; Imamura Y; Anzai N; Akakura K; Nishio K; Ichikawa T
Anticancer Res; 2024 Feb; 44(2):639-647. PubMed ID: 38307556
[TBL] [Abstract] [Full Text] [Related]
8. Nomogram for predicting the overall survival and cancer-specific survival of patients with intraductal carcinoma of the prostate.
Cui Y; Lin J; Sun D; Zhang H; Diao T; Fu Q
J Cancer Res Clin Oncol; 2024 Jan; 150(2):45. PubMed ID: 38281261
[TBL] [Abstract] [Full Text] [Related]
9. The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant Prostate cancer (mCRPC) Treated with Abiraterone or Enzalutamide.
Halabi S; Guo S; Park JJ; Nanus DM; George DJ; Antonarakis ES; Danila DC; Szmulewitz RZ; McDonnell DP; Norris JD; Lu C; Luo J; Armstrong AJ
Clin Cancer Res; 2024 Mar; 30(6):1152-1159. PubMed ID: 38236581
[TBL] [Abstract] [Full Text] [Related]
10. Aggressive prostatic adenocarcinoma with urothelial-like morphology, with frequent CK7/CK20/HMWK expression and occasional diffuse neuroendocrine features: A clinicopathologic study of 12 cases.
Nguyen NJ; Sherman C; van der Kwast TH; Downes MR
Pathol Res Pract; 2024 Feb; 254():155105. PubMed ID: 38218041
[TBL] [Abstract] [Full Text] [Related]
11. The Value of Combined Detection of Serum psa, MALAT1 and TMPRSS2-ETV1 in Evaluating the Progress and Prognosis of Prostate cancer.
Zhao G; Pan Z; Wang P
Arch Esp Urol; 2023 Oct; 76(8):555-562. PubMed ID: 37960954
[TBL] [Abstract] [Full Text] [Related]
12. Lifetime Follow-Up of a Patient with Metastatic Prostate cancer Undergoing Multiple Surgical Resections: A Case Report.
Nanashima A; Nagayasu T; Yamasaki N; Tsuchiya T; Matsumoto K; Tagawa T; Arai J
Am J Case Rep; 2023 Nov; 24():e941668. PubMed ID: 37939016
[TBL] [Abstract] [Full Text] [Related]
13. Cost-Effectiveness Analysis of Atezolizumab versus Platinum-Based Chemotherapy as First-Line Treatment for Patients with Unresectable Advanced Non-small Cell lung cancer with PD-L1 Expression Status in Japan.
Chisaki Y; Nakano H; Minamide J; Yano Y
Clin Drug Investig; 2023 Nov; 43(11):839-850. PubMed ID: 37891362
[TBL] [Abstract] [Full Text] [Related]
14. Latin America and the Caribbean Code Against cancer 1st Edition: Medical interventions including hormone replacement therapy and cancer screening.
Baena A; Paolino M; Villarreal-Garza C; Torres G; Delgado L; Ruiz R; Canelo-Aybar C; Song Y; Feliu A; Maza M; Jeronimo J; Espina C; Almonte M
Cancer Epidemiol; 2023 Oct; 86 Suppl 1():102446. PubMed ID: 37852728
[TBL] [Abstract] [Full Text] [Related]
15. Diagnostic Performance of PSMA-Based 18 F-DCFPyL PET/CT in Prostate cancer Patients After Definitive Treatment With psa Level ≤0.2 ng/mL.
Lu Y; Wilson ZJ; Xu G; Xu Z; Pan T; Wei P
Clin Nucl Med; 2023 Dec; 48(12):1021-1027. PubMed ID: 37801580
[TBL] [Abstract] [Full Text] [Related]
16. Immunotherapy Guided by Immunohistochemistry PD-L1 Testing for Patients with NSCLC: A Microsimulation Model-Based Effectiveness and Cost-Effectiveness Analysis.
Rui M; Wang Y; Li Y; Fei Z
BioDrugs; 2024 Jan; 38(1):157-170. PubMed ID: 37792142
[TBL] [Abstract] [Full Text] [Related]
17. Secondary Squamous Cell Carcinoma of Prostate: A Case Report.
Chen Q; Ye J; Li X; Chen R; Zeng S
Arch Esp Urol; 2023 Jun; 76(4):309-312. PubMed ID: 37455530
[TBL] [Abstract] [Full Text] [Related]
18. Synthesis and characterization of Hypsizygus ulmarius extract mediated silver nanoparticles (AgNPs) and test their potentiality on antimicrobial and anticancer effects.
Manimaran K; Yanto DHY; Anita SH; Nurhayat OD; Selvaraj K; Basavarajappa S; Hashem MI; Palanisamy G; Lin MC; Kumarasamy K
Environ Res; 2023 Oct; 235():116671. PubMed ID: 37454804
[TBL] [Abstract] [Full Text] [Related]
19. [HIFU therapy of localized prostate cancer using image-guided robotic HIFU Focal One].
Govorov AV; Vasilyev AO; Alaverdyan AI; Kolontarev KB; Pushkar DY
Urologiia; 2023 May; (2):83-89. PubMed ID: 37401710
[TBL] [Abstract] [Full Text] [Related]
20. Free psa and Clinically Significant and Fatal Prostate cancer in the PLCO Screening Trial.
Yim K; Ma C; Carlsson S; Lilja H; Mucci L; Penney K; Kibel AS; Eggener S; Preston MA
J Urol; 2023 Oct; 210(4):630-638. PubMed ID: 37384841
[TBL] [Abstract] [Full Text] [Related]
[Next]
